On May 28, 2021 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations (Press release, Spectrum Pharmaceuticals, MAY 28, 2021, View Source [SID1234583270]). This poster presentation will be available at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting being held June 4-8, 2021. Details of the presentation is as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: CNS activity of poziotinib in NSCLC with exon 20 insertion mutations
Speaker: Xiuning Le, M.D., Ph.D.
Poster Session: Lung Cancer – Non-small Cell Metastatic
Date and Time: June 4, 2021, available for on demand viewing beginning at 9 a.m. ET
Abstract Number: 9093

The poster presentations will be available for viewing by registered participants during the conference via the ASCO (Free ASCO Whitepaper) website beginning on June 4, 2021.